
Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate
Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in…












